|
valemetostat tosylate Clinical Trials
4 actively recruiting trials across 3 locations
No change since May 2026
Also known as: DS-3201b, valemetostat
Pipeline
Phase 1: 1Phase 2: 2Phase 1/2: 1
Top Sponsors
- Daiichi Sankyo2
- Gustave Roussy, Cancer Campus, Grand Paris1
- Alliance for Clinical Trials in Oncology1
Indications
- Cancer4
- Clear Cell Endometrial Carcinoma1
- Castration-Resistant Prostate Carcinoma1
- Solid Tumor Malignancies1
- Stage IVB Prostate Cancer AJCC v81
Other1 trial
Tucson, Arizona1 trial
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Banner University Medical Center - Tucson
Phase 2
Irvine, California1 trial
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
City of Hope At Orange County Lennar Foundation Cancer Center
Phase 1
La Jolla, California1 trial
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
University of California San Diego (Ucsd)-Moores Cancer Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.